Expression of MMP-9 and TIMP-1 in lesions of systemic sclerosis and its implications

Abstract

In order to investigate the role of MMP-9 and TIMP-1 in the pathogenesis of systemic sclerosis, the expression of MMP-9 and TIMP-1 was immunohistochemically detected in skin lesions of the patients with diffuse cutaneous systemic sclerosis, skin lesions of the patients with limited cutaneous systemic sclerosis, and skin tissues of normal subjects. The results showed that the expression of MMP-9 in lesions of diffuse cutaneous systemic sclerosis was significantly lower than that of normal skins (P<0.05). However, no significant difference in the level of MMP-9 in the limited cutaneous systemic sclerosis and normal skin was found. Meanwhile, the expression of TIMP-1 in lesions of diffuse cutaneous systemic sclerosis and limited cutaneous systemic sclerosis were significantly higher than that of normal skins (both P<0.05). It was suggested that the expression of MMP-9 and TIMP-1 might play an important role in the development of systemic sclerosis.

Keywords

MMP-9 / TIMP-1 / systemic sclerosis

References

[1] KimW. U., MinS. Y., ChoM. L., et al.. Elevated matrix metalloproteinase-9 in patients with systemic sclerosis. Arthritis Res Ther, 2005, 7(1): R71-R79

[2] GerstmeierH., GabrielliA., MeurerM., et al.. Levels of type IV collagen and laminin fragments in serum from patients with progressive systemic scleroderma. J Rheumatol, 1988, 15: 969-972

[3] JimenezS. A., FeldmanG., BasheyR. I., et al.. Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis fibroblasts. Biochem J, 1986, 237(3): 837-843

[4] HulboyD. L., RudolphL. A., MatrisianL.M.. Matrix metalloproteinases as mediators of reproductive function. Mol Hum Reprod, 1997, 3(1): 27-45

[5] JacksonC. J., NguyenM.. Human microvascular endothelial cells differ from macrovascular endothelial cells in their expression of matrix metalloproteinases. Int J Biochem Cell Biol, 1997, 29(10): 1167-1177

[6] KikuchiK., KuboM., HoashiT., et al.. Decreased MMP-9 activity in the serum of patients with diffuse cutaneous systemic sclerosis. Clin Exp Dermatol, 2002, 27(4): 301-305

[7] GiannelliG., IannoneF., MarinosciF., et al.. The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension. Curr Med Res Opin, 2005, 21(3): 327-332

[8] KikuchiK., KadonoT., FurueM., et al.. Tissue inhibitor of metalloproteinase 1 (TIMP-1) may be an autocrine growth factor in scleroderma fibroblasts. J Invest Dermatol, 1997, 108: 281-284

[9] OverallC.M., WrataJ. L., SodekJ.. Transcriptional and posttranscriptional regulation of 72 kDa gelatinase/type IV collagenase by transforming growth factor-b1 in human fibroblasts. J Biol Chem, 1991, 266: 14064-14071

[10] IhnH.. Autocrine TGF-beta signaling in the pathogenesis of systemic sclerosis. J Dermatol Sci, 2008, 49(2): 103-113

[11] XiaoR., LiuF. Y., LuoJ. Y., et al.. Effect of small interfering RNA on the expression of connective tissue growth factor and type I and III collagen in skin fibroblasts of patients with systemic sclerosis. Br J Dermatol, 2006, 155(6): 1145-1153

[12] VerrecchiaF., MauvielA., FargeD.. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev, 2006, 5(8): 563-569

[13] YazawaN., KikuchiK., IhnH., et al.. Serum levels of tissue inhibitor of metalloproteinases 2 in patients with systemic sclerosis. J Am Acad Dermatol, 2000, 42: 70-75

[14] Young-MinS. A., BeetonC., LaughtonR., et al.. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud’s phenomenon, and in normal controls. Ann Rheum Dis, 2001, 60(9): 846-851

[15] ToubiE., KesselA., GrushkoG., et al.. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol, 2002, 20(2): 221-224

[16] Young-MinS. A., BeetonC., LaughtonR., et al.. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud’s phenomenon, and in normal controls. Ann Rheum Dis, 2001, 60(9): 846-851